Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313756 | 0.80 | ALDH1A1 (0.40) | NR1D1LMNAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL27464783 | 0.78 | NR1D1 (0.52) | NR1D1LMNAMAPTALDH1A1TDP1 | |
| SCHEMBL221788 | 0.78 | MTNR1A (0.53) | LMNAMAPTALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL3719769 | 0.77 | ALDH1A1 (0.52) | LMNAMAPTBACE1ALDH1A1TDP1 | |
| SCHEMBL25695965 | 0.77 | MAPT (0.48) | NR1D1LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13215501 | 0.76 | ALDH1A1 (0.56) | NR1D1LMNAMAPTALDH1A1TDP1 | |
| SCHEMBL16003471 | 0.76 | ALDH1A1 (0.45) | LMNAMAPTBACE1ALDH1A1TDP1 | |
| SCHEMBL30871973 | 0.76 | ALDH1A1 (0.45) | LMNAMAPTBACE1ALDH1A1TDP1 | |
| SCHEMBL22954820 | 0.75 | CHEK1 (0.43) | LMNAMAPTBACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30879022 | 0.75 | LMNA (0.44) | LMNAMAPTBACE1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | NR1D1 1743/4885LMNA 3341/4885MAPT 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.